Immunohistochemistry Analysis for Interleukin-6 Expression from the Tumor Tissue

Author(s): Dhamia K. Suker, Adnan I. AL- Badran, Emad K. Abbas, Saad Abudl baqi Abdullah

The cytokines including interleukins considered an important component of the body's immunity against inflammatory conditions and cancer diseases, and is an important factor in inducing the symptoms of wasting weight in cancer patients. Therefore, the knowledge and the study of these factors and their impact, production, particularly interleukin-6 gene expression and identification to recognize the presence and production of this factor in the tissues of patients through immunohistochemistry technique and gene expression. The study included 40 samples from different types of malignant tumor biopsy and (7) samples for benign tumor used as control. Immunohistochemistry (IHC) analysis revealed that there was an increase in the production of interleukin -6 which appeared as brown precipitate in the cytoplasm of cancer cell as positive staining , while, the benign tumor tissues (control ) showed negative staining.

IL-6, immunohistochemistry, tumor tissues

1. Ajura ,AJ.;Sumairi, I.; Lau ,SH.(2007). The use of immunohistochemistry in an oralpathology laboratory, Malays. Jpathol .29:101-105.
2. Ancrile, B.; Lim, KH.; Counter, CM .(2007). Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 21: 1714-1719.
3. Bai, L.; Yu, H.; Wang, H.; Su, H.; Zhao, J.;et al. (2013). Genetic single nucleotide polymorphisms of inflammation-related factors associated with risk of lung cancer. Med Oncol 30: 414.
4. Bayliss, TJ.; Smith, JT.; Schuster, M.; Dragnev, KH.; Rigas, JR .(2011). A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 11: 1663-1668.
5. Becker, C..; Fantini, M.C.; Wirtz, S.; Nikolaev, A.; Lehr, H.A.; Galle, P.R.; Rose John & Neurath, M.F. (2005). IL-6 Signaling Promotes Tumor Growth in Colorectal Cancer. Cell Cycle 4:2, 217-220.
6. Burger,Renate.(2013).Impact of Interleukin-6 in Hematological Malignancies. Transfus Med Hemother 40:336–343.
7. Cardillo, Maria Rosaria. And Ippoliti , Flora.(2006). IL-6, IL-10 and HSP-90 Expression in Tissue microarrays from Human prostate cancer assessed by computer- assisted Image Analysis.Anticancer research 26:3409-3416.
8. Chen, J.; Liu, RY.; Yang, L.; Zhao, J.; Zhao, X. et al. (2013a). A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk. J Cancer Res Clin Oncol 139: 231-242.
9. Chen, J.; Liu, RY.; Yang, L.; Zhao, J.; Zhao, X. et al. (2013b). A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk. J Cancer Res Clin Oncol 139: 231-242.
10. Chen, Miao-Fen.; Paul-Yang ,Lin.; Ching-Fang, Wu.; Wen-Cheng, Chen.; Chun-Te, Wu.(2013a).IL-6 Expression Regulates Tumorigenicity and Correlates with Prognosis in Bladder Cancer. Plosone Volume 8. Issue 4.
11. Chen, M.-F.; Chen, P.-T .; Lu, M. S. ; Lin, P. Y .; Chen, W.-C. and Lee, K.-D. (2013b). “IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus, Molecular Cancer, vol. 12, article 26.
12. Chen, D., L. Jin, L. Zhu, X. Mou, S. Wang, and C. Mao.( 2013). “Expressions and correlations of let-7a and IL-6 in esophageal squamous cell carcinoma,” Chinese Journal of Cellular and Molecular Immunology, vol. 29, no. 11, pp. 1181–1184.
13. Chung, Yuan-Chiang.; Yuan-Liang, Chaen.; and Chi-Pin, Hsu.(2006). Clinical Significance of Tissue Expression ofInterleukin-6 in Colorectal Carcinoma. ANTICANCER RESEARCH 26: 3905-3912.
14. Cuello AC. (Ed.), Immunohistochemistry II, New York: Wiley Press 1993.
15. Culig ,Z.; Steiner, H.; Bartsch, G.; Hobisch, A. (2005). Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem; 95: 497-505.
16. Dvorakova, Katerina,; Claire, M.; Payne, Lois Ramsey.; Hana, Holubec.;Richard, Sampliner.; Jessica, Dominguez.; Bohuslav, Dvorak.; Harris, Bernstein.;Carol, Bernstein.; Anil, Prasad.; Ronnie ,Fass.;Haiyan, Cui.; and Harinder, Garewal.(2004). Increased Expression and Secretion of Interleukin-6 in Patients with Barrett’s Esophagus. Vol. 10: 2020–2028.
17. Engelhardt ,P. F.;. Seklehner, S.; Brustmann, H.; Lusuardi, L. and Ried, C. R. (2014). “Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV,” Scandinavian Journal Of Urology, vol. 49, no. 2, pp. 120–126.
18. Fain ,JN.; Madan, AK.; Hiler ,ML.; Cheema, P.; Bahouth, SW.( 2004).Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology; 145: 2273-2282.
19. Kayamori. Kou.; Kei, Sakamoto.;Tomoki, Nakashima.; Hiroshi, Takayanagi.;Kei-ichi, Morita.; Ken, Omura.; Su Tien, Nguyen.;Yoshio, Miki.; Tadahiro ,Iimura.;Akiko ,Himeno.; Takumi ,Akashi.; Hisafumi, Yamada-Okabe.; Etsuro, Ogata.;and Akira ,Yamaguchi. (2010).Roles of Interleukin-6 and ParathyroidHormone-Related Peptide in Osteoclast FormationAssociated with Oral Cancers. Vol. 176, No. 2:968-980.
20. Kishimoto,T.(2010).IL-6: from its discovery to clinical applications. Int Immunol; 22:347–352.
21. Kishimoto, T.; Akira, S.; Narazaki, M.; Taga, T.(1995). Interleukin- 6 family of cytokines and gp130. Blood; 86:1243–1254.
22. Kobawala ,Toral.;, Trupti, P.; Trivedi, I.; Kinjal, K. ;Gajjar, Darshita.; Patel, H.;
23. Girish, H. and Nandita R, Ghosh.(2015). Significance of Interleukin-6 in Papillary Thyroid Carcinoma. Volume 2016, Article ID 6178921, 12 pages.
24. Labovsky ,V., Martinez, L. M.; Davies ,K. M. et al. (2015). “Association between ligands and receptors related to the progression of early breast cancer in tumor epithelial and stromal cells,” Clinical Breast Cancer, vol. 15, no. 1, pp. e13–e21.
25. Lonnroth ,C..; Gelin, J. ; Lundholm, K. .(1994).Expression of interlukin-6 in tumor –bearing mice with cytokine dependent cachexia .international journal of oncology. Volume 5 issue 2:329-336.
26. Martignoni ,Marc E., Phillip, Kunze.; Wulf, Hildebrandt. et al.(2005). Role of Mononuclear Cells and Inflammatory Cytokines in Pancreatic Cancer – Related cachexia.vol.11, No.16:5802-5808.
27. Mihara ,M.; Hashizume, M.; Yoshida, H.; Suzuki, M.; Shiina, M.(2012). IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond); 122:143–159.
28. Paule, Bernard.; Jacqueline, Belot.; Christiane ,Rudant.; Colette, Coulombel.; Claude Clément ,Abbou.(2000). The importance of IL-6 protein expression in primary human renal cell carcinoma: an immunohistochemical study. J Clin Pathol; 53:388–390.
29. Songur,N.; Kuru, B.; Kalkan, F.; Ozdilekcan, C.; Cakmak, H. et al. (2004). Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori 90: 196-200.
30. Tan ,Xiaohong.; Julian ,Carretero.; Zhao, Chen.; Jishuai, Zhang.; Yanxiao, Wang.; Jicheng, Chen.; Xiubin, Li.; Hui, Ye.; Chuanhao, Tang.; Xuan ,Cheng.; Ning ,Hou.; Xiao, Yang.; Kwok-Kin ,Wong. (2013).Loss of p53 Attenuates the Contribution of IL-6 Deletion on Suppressed Tumor Progression and Extended Survival in Kras-Driven Murine Lung Cancer. Vol. 8 , Issue 11 : e80885.
31. Wang, Huaqian .; Xiao-Xing, Cui.; Susan ,Goodin.; Ning, Ding.; Jeremiah, Van Doren.; Zhoyun ,Du.; Mou-Tuan, Huang.; Yue, Liu.; Xiaodong, Cheng.; Robert, S. and Xi, zheng.(2014). Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib. 31: 835-841.
32. Wang, Z X.; Si, AXu. et al. ( 2013). “Activation of STAT3 in human gastric cancer cells via interleukin (IL)-6-type cytokine signaling correlates with clinical implications,” PLOS ONE, vol. 8, no. 10, Article ID e75788.
33. Wojcik ,E.; Jakubowicz, J.; Skotnicki ,P.; Sas-Korczyńska, B.; Kulpa, JK .(2010). IL-6 and VEGF in small cell lung cancer patients. Anticancer Res 30: 1773-1778.